Daewoong Co., Ltd. (KRX:003090)
27,500
-1,400 (-4.84%)
Feb 26, 2026, 9:50 AM KST
Daewoong Revenue
Daewoong had revenue of 542.18B KRW in the quarter ending September 30, 2025, with 5.10% growth. This brings the company's revenue in the last twelve months to 2.06T, up 9.35% year-over-year. In the year 2024, Daewoong had annual revenue of 1.94T with 6.79% growth.
Revenue (ttm)
2.06T
Revenue Growth
+9.35%
P/S Ratio
0.57
Revenue / Employee
5.42B
Employees
379
Market Cap
1.18T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.94T | 123.08B | 6.79% |
| Dec 31, 2023 | 1.81T | 116.50B | 6.86% |
| Dec 31, 2022 | 1.70T | 185.96B | 12.30% |
| Dec 31, 2021 | 1.51T | 156.04B | 11.51% |
| Dec 31, 2020 | 1.36T | -10.34B | -0.76% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GC Biopharma | 1.93T |
| Chong Kun Dang Pharmaceutical | 1.68T |
| Daewoong Pharmaceutical | 1.54T |
| Dong-A Socio Holdings | 1.40T |
| Boryung | 1.03T |
| DongKook Pharmaceutical | 894.93B |
| Huons Global | 825.44B |
| JW Pharmaceutical | 764.21B |
Daewoong News
- 4 weeks ago - AEON Biopharma Completes BPD Type 2a Meeting With FDA - Nasdaq